Kriya Series C Funding Round Investors: Complete Guide to the $430M+ Financing

The Kriya Series C funding round investors attracted significant attention across the biotechnology and gene therapy sectors because of the scale of the financing and the strategic backing behind Kriya Therapeutics.

Kriya announced its original $270 million Series C financing on May 16, 2022. The financing was led by Patient Square Capital, with participation from Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital, and other undisclosed investors.

The capital was intended to advance Kriya’s gene therapy pipeline while continuing to scale its engineering, manufacturing, and computational platforms. The financing was therefore significant not only because of its size but also because it supported Kriya’s strategy of building an integrated platform for designing, developing, and manufacturing gene therapies.

What Was the Kriya Series C Funding Round?

Kriya Therapeutics announced a $270 million Series C financing on May 16, 2022. Patient Square Capital led the financing, while a broad group of biotechnology, healthcare, and investment organizations participated.

The publicly identified investors included:

• Patient Square Capital
• Bluebird Ventures
• CAM Capital
• Dexcel Pharma
• Foresite Capital
• JDRF T1D Fund
• Lightswitch Capital
• Narya Capital
• QVT
• Transhuman Capital
• Other undisclosed investors

According to Kriya, the proceeds were intended to support the advancement of its pipeline and the continued scaling of its engineering, manufacturing, and computational platforms.

This financing represented an important stage in Kriya’s effort to create an integrated gene therapy company rather than focusing exclusively on an individual therapeutic candidate.

Kriya Series C Investors

The Kriya Series C investors represented a diverse group of financial and strategic organizations.

Patient Square Capital served as the lead investor, while the remaining publicly disclosed participants provided additional financial support. The diversity of the investor group reflected interest in Kriya’s technology platform, therapeutic pipeline, manufacturing capabilities, and broader gene therapy strategy.

Kriya Series C Investor Comparison

Kriya officially identified these investors in its May 2022 announcement of the $270 million Series C financing.

Patient Square Capital: Lead Kriya Series C Investor

Patient Square Capital played the most prominent role in the Series C financing because it served as the lead investor.

Patient Square’s involvement was strategically important because the firm specializes in healthcare investments. Jim Momtazee, Managing Partner of Patient Square Capital, also served on Kriya’s board.

The investment supported Kriya’s efforts to scale its gene therapy platform and advance its pipeline. Patient Square has remained an important Kriya investor beyond Series C and later co-led the company’s $320 million Series D financing in 2025.

This continued relationship demonstrates the long-term nature of Patient Square’s involvement with Kriya.

Bluebird Ventures and Kriya

Bluebird Ventures was one of the publicly disclosed participants in Kriya’s Series C financing.

The relationship also extends further back in Kriya’s financing history. Bluebird Ventures participated in Kriya’s $80.5 million Series A financing announced in 2020, demonstrating that its relationship with the company predates Series C.

Bluebird’s continued participation highlights the confidence that some early investors placed in Kriya’s gene therapy platform as the company moved through later financing stages.

CAM Capital’s Participation

CAM Capital participated in Kriya’s $270 million Series C financing.

The investment formed part of a larger financing syndicate that brought together healthcare, biotechnology, and institutional investors. Kriya’s integrated model was designed to combine therapeutic development with its technology, manufacturing, research, and computational capabilities.

The Series C funding provided capital to continue developing this infrastructure while advancing the company’s therapeutic pipeline.

Foresite Capital and Kriya’s Gene Therapy Strategy

Foresite Capital was another investor named by Kriya in connection with the Series C financing.

Foresite had also participated in Kriya’s Series A financing in 2020, when the company was developing its early gene therapy platform.

Kriya’s technology-focused strategy has emphasized the use of computational tools, engineering, high-throughput screening, and scalable manufacturing to address some of the challenges associated with gene therapy development.

The Series C financing enabled the company to continue scaling these capabilities.

JDRF T1D Fund

The JDRF T1D Fund was among the investors identified in Kriya’s Series C announcement.

Its participation was particularly relevant to Kriya’s work involving metabolic diseases and diabetes. Kriya’s current pipeline includes an investigational gene therapy candidate for Type 1 Diabetes, identified as KRIYA.288.

Kriya’s broader strategy is to develop durable medicines intended to address chronic diseases affecting large patient populations.

Narya Capital

Narya Capital participated in Kriya’s Series C financing and had also been involved in earlier company financing.

Narya participated in Kriya’s Series A financing in 2020, alongside investors including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, and others.

Its participation in later financing demonstrates continued investor interest in Kriya’s technology and development platform.

QVT and Transhuman Capital

QVT and Transhuman Capital were also named among the investors in Kriya’s Series C financing.

Both organizations had connections to Kriya’s earlier financing history. QVT participated in the company’s Series A, while Transhuman Capital led Kriya’s initial seed financing and also participated in Series A.

This makes them notable members of Kriya’s longer-term investor base.

Dexcel Pharma and Lightswitch Capital

Dexcel Pharma and Lightswitch Capital were additional participants in Kriya’s Series C financing.

Dexcel Pharma was also identified as a Series A investor in 2020.

Together with the other investors, their participation expanded the financial backing available to Kriya as it scaled its gene therapy technology, manufacturing capabilities, and clinical development programs.

How Much Did Kriya Raise in Series C?

The original Kriya Series C funding round was $270 million.

This made Series C one of the company’s largest financing milestones at that point. Kriya had previously raised $80.5 million in Series A in 2020 and $100 million in Series B in 2021.

The Series C financing therefore represented a substantial increase in the amount of capital available to the company as it moved toward advancing its pipeline and scaling its integrated platform.

How Kriya Planned to Use the Series C Capital

Kriya stated that the Series C proceeds would support the advancement of its pipeline and continued scaling of its engineering, manufacturing, and computational platforms.

This was consistent with Kriya’s business model, which integrates multiple functions rather than separating therapeutic development from manufacturing and technology infrastructure.

The company described its ecosystem as incorporating technology, manufacturing, research and development, and therapeutics.

Such integration can be particularly important in gene therapy because the development process involves complex biological engineering, vector production, process development, quality systems, analytical testing, and clinical translation.

Kriya’s Gene Therapy Platform

Kriya’s platform has been built around the idea that gene therapy development can be improved through the combination of computational technology, engineering, data, and manufacturing infrastructure.

In its 2022 financing announcement, Kriya highlighted its proprietary computational platform, in-house manufacturing infrastructure, and rational design toolkit. The company also described its SIRVE™ machine-learning-enabled technology and cloud architecture for integrating large datasets generated through high-throughput screening, next-generation sequencing, and algorithmic data mining.

The Series C financing helped provide resources for continued development of these capabilities.

Kriya’s Manufacturing Infrastructure

Manufacturing has been a central part of Kriya’s strategy.

The company established scalable GMP manufacturing infrastructure in Research Triangle Park, North Carolina, designed to support in-house production from early development through later phases.

This infrastructure was intended to help Kriya develop and implement manufacturing technologies and processes capable of supporting consistent, large-scale production.

For a gene therapy company, this capability can be strategically important because manufacturing complexity can become a major constraint as programs advance toward clinical development and commercialization.

Kriya’s Therapeutic Pipeline

Kriya has continued developing a broad portfolio of investigational durable medicines.

Its current pipeline includes programs addressing:

• Geographic Atrophy — KRIYA.825
• Thyroid Eye Disease — KRIYA.586
• Type 1 Diabetes — KRIYA.288
• Steatotic Liver Disease — KRIYA.497
• Trigeminal Neuralgia — KRIYA.748

Kriya describes these as investigational medicines and emphasizes its goal of developing treatments that can provide lasting benefits from a single administration.

The company’s pipeline has evolved since its 2022 Series C announcement, making it important to distinguish historical pipeline descriptions from the company’s current portfolio.

Why the Series C Was Important for Kriya

The significance of Kriya’s Series C financing extends beyond the $270 million headline figure.

Gene therapy development requires significant investment in research, engineering, manufacturing, regulatory preparation, clinical development, and specialized infrastructure.

Kriya’s strategy was to build many of these capabilities internally.

The Series C therefore provided capital not only for individual therapeutic programs but also for the infrastructure intended to support multiple programs simultaneously.

This platform-based approach is particularly important when the objective is to develop therapies for common chronic diseases, where manufacturing scale and cost can become major barriers.

Kriya’s Integrated Business Model

Kriya has described itself as a fully integrated gene therapy company, with operations spanning technology, manufacturing, R&D, and therapeutics.

The company’s current positioning has evolved further, with Kriya describing itself as “The Durable Medicines Company.” Its stated goal is to build an integrated product engine in which research, development, and manufacturing operate together.

This strategy represents an important part of understanding why investors were willing to provide substantial capital.

Rather than viewing Kriya simply as a company developing individual drug candidates, investors were also backing the underlying infrastructure and technology platform.

Kriya Funding After Series C

Kriya’s financing history continued after its Series C.

In September 2025, Kriya announced the closing of a $320 million Series D financing. The round was co-led by Patient Square Capital and Premji Invest, with participation from Peter Thiel, Narya Capital, The T1D Fund, and other long-term investors.

Kriya stated that the Series D proceeds would support clinical trials of five lead pipeline programs as well as continued investment in its research and manufacturing engine.

The company’s subsequent financing confirms that the Series C was part of a broader capital strategy supporting the development and scaling of Kriya’s platform.

Kriya’s Progress After Series C

Kriya continued to advance its pipeline after the Series C financing.

In January 2024, the company reported that it had a $325 million cash balance and expected its first gene therapy product candidate to enter the clinic during 2024, with up to five programs potentially entering the clinic by the end of 2025.

The company identified ophthalmology, metabolic disease, and neurology as major therapeutic areas at that stage.

By 2025, Kriya had progressed to a Series D financing supporting clinical trials across several programs.

Kriya Series C Funding Round Investors: Key Takeaways

The Kriya Series C funding round investors supported a major stage in the company’s development as a gene therapy platform.

The key facts include:

• The Series C was announced in May 2022.
• The original financing totaled $270 million.
• Patient Square Capital led the financing.
• Publicly identified investors included Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, and Transhuman Capital.
• The financing supported Kriya’s therapeutic pipeline.
• Capital was also allocated toward scaling the company’s engineering, manufacturing, and computational platforms.
• Kriya operates an integrated model combining technology, manufacturing, R&D, and therapeutics.
• Patient Square Capital continued backing Kriya in its later financing history, including the $320 million Series D in 2025.

FAQ

Who led Kriya’s Series C funding round?

Patient Square Capital led Kriya Therapeutics’ $270 million Series C financing announced in May 2022.

How much did Kriya raise in Series C?

Kriya raised $270 million in its Series C financing announced on May 16, 2022.

Who invested in Kriya Series C?

Publicly identified investors included Patient Square Capital, Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT, and Transhuman Capital, along with other undisclosed investors.

What was Kriya’s Series C funding used for?

The funding was intended to advance Kriya’s gene therapy pipeline and scale its engineering, manufacturing, and computational platforms.

Who invested in Kriya after Series C?

Kriya later raised a $320 million Series D in 2025, co-led by Patient Square Capital and Premji Invest, with participation from Peter Thiel, Narya Capital, The T1D Fund, and other investors.

Final Thoughts on Kriya Series C Investors

The Kriya Series C funding round investors provided substantial financial support for Kriya Therapeutics at an important stage of its development.

The $270 million Series C, led by Patient Square Capital, brought together a diverse group of investors with interests across biotechnology, healthcare, life sciences, technology, and institutional investment.

The financing was important because Kriya was not simply raising money to advance one therapeutic candidate. The company was also building an integrated system encompassing gene therapy research, computational technology, engineering, and manufacturing.

Kriya’s subsequent development and its $320 million Series D financing in 2025 demonstrate that the company’s capital strategy continued well beyond Series C.

For anyone researching Kriya Series C funding round investors, the central takeaway is clear: the 2022 financing represented a major vote of confidence in Kriya’s integrated approach to gene therapy development and its ambition to make durable medicines scalable for diseases affecting millions of people.